Ashley Gallagher, Editor

Clinical trial participants who took the drug lost up to 52 lb., or 24 kg, in the 72-week, phase 3 study.

Students from the University of the Sciences’ Philadelphia College of Pharmacy triumphed.

The advanced cell therapy is under development as an allogeneic hematopoietic stem cell transplant for patients with hematologic malignancies.

The company’s analysis shows data for the automated insulin delivery system for both T1D and T2D.

Data from the study shows a strong immune response in this age group following this dose, with no new safety signals.

FT218 is an investigational formulation of sodium oxybate that is designed to be taken once at bedtime for the treatment of excessive daytime sleepiness for individuals with narcolepsy.

Investigators observe strong immunogenicity profile in study participants aged 5 to 17 years 1 month after the primary vaccination series.

Individuals with diabetes, a higher body mass index, or a history of hospitalization are more likely to develop the condition, the analysis shows.

Of these visits, approximately 11%, or 8 million, resulted in antibiotic prescriptions, foremost commonly for illnesses that are not caused by a bacterial infection, such as bronchitis, non-bacterial skin conditions, and viral respiratory-tract infections.

STRIDE regimen of a single priming dose added to Imfinzi is the first dual immune checkpoint blockage regimen to improve overall survival in a phase 3 trial in this setting.

The PREVENT-19 study evaluates the immunogenicity and safety of a third dose of NVX-CoV2373 in children aged 12 to 17 years.

Intra Cellular Therapies’ Lumateperone is available in the 10.5- and 21-mg strengths and can also be used to treat depressive episodes associated with bipolar I or II disorder.

Belumosudil is indicated to treat individuals aged 12 years and older with chronic graft-versus-host disease who have received at least 2 prior systemic therapy treatments without success.

In a case study, the symptoms associated with the rash are fatigue, migratory lower extremity joint pain, and swelling of the ankles and feet.

ARCT-154 demonstrates 95% efficacy overall for prevention of severe disease, including related deaths.

Three in 5 say it is hard to get kids to eat well-balanced diets, because of not eating enough fruits and vegetables, pickiness, and other reasons.

FDA-approved Disulfiram can safely reduce anxiety levels in rodents, analysis from the Tokyo University of Sciences and other Japan institutes finds.

DuoBody, for treatment of relapsed/refractory large B-cell lymphoma, demonstrates an overall response rate of 63.1%.

New analysis demonstrates that physical activity improves cognitive health, thus staving off dementia.

The application is based on positive results from the ASCEND phase 3 clinical trial, assessing the efficacy and safety of daprodustat for the treatment of anemia from chronic kidney disease.

The updated efficacy analyses showed that tislelizumab in combination with chemotherapy continued to demonstrate a clinically significant progression-free survival benefit for individuals with recurrent or metastatic nasopharyngeal cancer.

The analyses are shared at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, Louisiana.

Analysis indicates that quitting provides roughly the same benefit as taking 3 medications together.

US segment to hit $121.8 billion in 2022, notes market research firm.

Among individuals taking the medication with standard-of-care topical corticosteroids, approximately 41% achieved clear or almost clear skin at 16 weeks.

Analyses are shared at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, Louisiana.

Session highlights novel agents that have recently entered, or will imminently enter, into phase 1 clinical trials.

Mylo Wells, PharmD, owner of Wells Hometown Drug and Wells Hometown Drug Keosauqua, aims to give back to the community where he grew up.

The investigational selective, covalent, and orally bioavailable KRASG12C¬ inhibitor shows a 57% confirmed overall response rate at the recommended dose of 200 mg twice daily.

Results are from an exploratory analysis of 34 patients who received at least 1 dose after disease progression or suboptimal response with ruxolitinib monotherapy